Supermicro Completes Independent Investigation into March 2026 Export-Control Matter
No evidence of senior management knowledge or company-level wrongdoing found.
Already have an account? Sign in.
No evidence of senior management knowledge or company-level wrongdoing found.
Sanofi has terminated the SAR448272 STAT6 degrader program. Nurix shares fell sharply in after-hours trading, but cash runway remains intact through 2029.
Block posted 22% gross profit growth in Q3, raised its annual outlook, and continues expanding AI tools across Cash App and Square.
DAUs rose 29% to 64.9M as product experiments and partnerships drove reacceleration. Beats on revenue and bookings plus raised guidance fueled a relief rally.
Be the first to know when deals break, stocks move, or biotech headlines hit.